Pharmacotherapy and Molecular Biomarkers of Metabolic Diseases
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (25 March 2026) | Viewed by 1067
Special Issue Editors
Interests: pharmacogenetics; molecular biomarkers; cardiovascular diseases; metabolic diseases; precision medicine; transcriptomics; inflammation; gene–environment interaction
Interests: pharmacogenetics; cardiovascular diseases; precision medicine; molecular biomarkers; translational medicine; pharmacotherapy; microbiota and cardiovascular diseases
Special Issue Information
Dear Colleagues,
Metabolic and cardiovascular diseases, such as type 2 diabetes, dyslipidemia, obesity, hypertension, and heart failure, remain among the leading causes of morbidity and mortality worldwide. These conditions often share overlapping pathophysiological mechanisms and frequently coexist, increasing clinical complexity and risk. Despite advances in pharmacological treatments, significant interindividual variability in drug responses and disease progression persists, highlighting the need for more personalized approaches.
This Special Issue aims to present original research at the intersection of pharmacotherapy and molecular biomarker discovery, with the goal of improving the diagnosis, prognosis, and treatment of metabolic and cardiovascular diseases. We invite contributions from clinical and experimental studies, including those addressing genetic, epigenetic, transcriptomic, proteomic, and metabolomic biomarkers, as well as research on pharmacodynamic and pharmacokinetic variability, and precision medicine strategies.
Relevant topics include, but are not limited to, the following:
- Biomarkers for treatment response, risk stratification, or disease monitoring.
- New therapeutic targets and molecular mechanisms of action.
- Pharmacogenomic and pharmacometabolic studies.
- Translational models linking omics data with clinical outcomes.
- Integration of molecular data into therapeutic decision-making.
We cordially invite researchers, clinicians, and interdisciplinary teams working in pharmacology, molecular biology, cardiometabolic medicine, and interdisciplinary research to contribute to this Special Issue. Whether your research is laboratory-based, clinical, or translational, we look forward to your contributions and promoting scientific exchange that supports the development of more effective and personalized therapies for cardiometabolic diseases.
Dr. Kathleen F. Saavedra Peña
Dr. Nicolás R. Saavedra Cuevas
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- molecular biomarkers
- cardiovascular diseases
- metabolic diseases
- precision medicine
- pharmacogenomics
- translational research
- omics technologies
- drug response variability
- personalized medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
